UH-232

UH-232
(IUPAC) ime
	cis-5-hidroksi-1-metil-2-(N,N-propilamino)tetralin
Klinički podaci
Identifikatori
CAS broj	95999-12-5
ATC kod	nije dodeljen
PubChem	123696
Hemijski podaci
Formula	C18H29NO
Mol. masa	275,428 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C18H29NO/c1-5-12-19(13-6-2)17-11-10-16-15(14(17)3)8-7-9-18(16)20-4/h7-9,14,17H,5-6,10-13H2,1-4H3 ; Key: BTOJYCTUJJHANF-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

UH-232 ((+)-UH232) je lek koji deluje mešoviti agonist-antagonist dopaminskih receptora koji je selektivan za pojedine podtipove. On je slab parcijalni agonist na D₃ podtipu,^[3] i antagonist na D₂Sh autoreceptorima u dopaminergičnim nervnim završecima.^[4]^[5] On uzrokuje otpuštanje dopamina u mozgu i ima stimulišuče dejstvo.^[6]^[7]^[8] On sprečava načina ponašanja koji je uzrokovan kokainom.^[9] On je ispitivan za primenu u lečenju šizofrenije. Ispitivanja su prekinuta jer je pogoršavao simptome.^[10]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Griffon N, Pilon C, Schwartz JC, Sokoloff P (1995). „The preferential dopamine D3 receptor ligand, (+)-UH232, is a partial agonist”. European journal of pharmacology 282 (1–3): R3–4. DOI:10.1016/0014-2999(95)00460-3. PMID 7498261.
↑ Waters N, Lagerkvist S, Löfberg L, Piercey M, Carlsson A (1993). „The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study”. European journal of pharmacology 242 (2): 151–63. DOI:10.1016/0014-2999(93)90075-S. PMID 8253112.
↑ Aretha, CW; Sinha, A; Galloway, MP (1995). „Dopamine D3-preferring ligands act at synthesis modulating autoreceptors”. The Journal of pharmacology and experimental therapeutics 274 (2): 609–13. PMID 7636720.
↑ Waters, N; Hansson, L; Löfberg, L; Carlsson, A (1994). „Intracerebral infusion of (+)-AJ76 and (+)-UH232: effects on dopamine release and metabolism in vivo”. European journal of pharmacology 251 (2–3): 181–90. DOI:10.1016/0014-2999(94)90399-9. PMID 8149975.
↑ Sotnikova, TD; Gainetdinov, RR; Grekhova, TV; Rayevsky, KS (2001). „Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study)”. Pharmacological research : the official journal of the Italian Pharmacological Society 43 (3): 283–90. DOI:10.1006/phrs.2000.0773. PMID 11401421.
↑ Millan, MJ; Seguin, L; Gobert, A; Cussac, D; Brocco, M (2004). „The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats”. Psychopharmacology 174 (3): 341–57. DOI:10.1007/s00213-003-1770-x. PMID 14985929.
↑ Piercey, MF; Lum, JT; Hoffmann, WE; Carlsson, A; Ljung, E; Svensson, K (1992). „Antagonism of cocaine's pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232”. Brain research 588 (2): 217–22. DOI:10.1016/0006-8993(92)91578-3. PMID 1393576.
↑ Lahti, AC; Weiler, M; Carlsson, A; Tamminga, CA (1998). „Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia”. Journal of neural transmission (Vienna, Austria : 1996) 105 (6–7): 719–34. DOI:10.1007/s007020050091. PMID 9826114.

Povezano

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Griffon N, Pilon C, Schwartz JC, Sokoloff P (1995). „The preferential dopamine D3 receptor ligand, (+)-UH232, is a partial agonist”. European journal of pharmacology 282 (1–3): R3–4. DOI:10.1016/0014-2999(95)00460-3. PMID 7498261.

[4] Waters N, Lagerkvist S, Löfberg L, Piercey M, Carlsson A (1993). „The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study”. European journal of pharmacology 242 (2): 151–63. DOI:10.1016/0014-2999(93)90075-S. PMID 8253112.

[5] Aretha, CW; Sinha, A; Galloway, MP (1995). „Dopamine D3-preferring ligands act at synthesis modulating autoreceptors”. The Journal of pharmacology and experimental therapeutics 274 (2): 609–13. PMID 7636720.

[6] Waters, N; Hansson, L; Löfberg, L; Carlsson, A (1994). „Intracerebral infusion of (+)-AJ76 and (+)-UH232: effects on dopamine release and metabolism in vivo”. European journal of pharmacology 251 (2–3): 181–90. DOI:10.1016/0014-2999(94)90399-9. PMID 8149975.

[7] Sotnikova, TD; Gainetdinov, RR; Grekhova, TV; Rayevsky, KS (2001). „Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study)”. Pharmacological research : the official journal of the Italian Pharmacological Society 43 (3): 283–90. DOI:10.1006/phrs.2000.0773. PMID 11401421.

[8] Millan, MJ; Seguin, L; Gobert, A; Cussac, D; Brocco, M (2004). „The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats”. Psychopharmacology 174 (3): 341–57. DOI:10.1007/s00213-003-1770-x. PMID 14985929.

[9] Piercey, MF; Lum, JT; Hoffmann, WE; Carlsson, A; Ljung, E; Svensson, K (1992). „Antagonism of cocaine's pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232”. Brain research 588 (2): 217–22. DOI:10.1016/0006-8993(92)91578-3. PMID 1393576.

[10] Lahti, AC; Weiler, M; Carlsson, A; Tamminga, CA (1998). „Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia”. Journal of neural transmission (Vienna, Austria : 1996) 105 (6–7): 719–34. DOI:10.1007/s007020050091. PMID 9826114.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]